TLR9 Antikörper (AA 100-290) (FITC)

Produktnummer ABIN5564254

Produktdetails anti-TLR9 Antikörper (FITC)

Target: TLR9 (Toll-Like Receptor 9 (TLR9))

Bindungsspezifität: AA 100-290

Reaktivität: Human, Maus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TLR9 Antikörper ist konjugiert mit FITC

Applikation: Flow Cytometry (FACS)

Spezifität: Recognizes human and mouse TLR9.

Kreuzreaktivität: Human, Maus

Aufreinigung: Protein G purified.

Immunogen: Recombinant human TLR9 protein (aa 100-290).

Klon: ABM1C51

Isotyp: IgG1

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: In 10 mM TRIS containing 150 mM NaCl and 0.05 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Short Term Storage: +4°C
Long Term Storage: +4°C
Stable for at least 6 months after receipt when stored at +4°C.

Haltbarkeit: 6 months

Details zu TLR9

Target: TLR9 (Toll-Like Receptor 9 (TLR9))

Andere Bezeichnung: TLR9 (TLR9 Produkte)

Synonyme: CD289 antikoerper, toll like receptor 9 antikoerper, toll-like receptor 9 antikoerper, TLR9 antikoerper, Tlr9 antikoerper

Hintergrund: TLR9 (Toll-like Receptor 9) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 is expressed by numerous cells of the immune system such as B lymphocytes, monocytes, natural killer (NK) cells and plasmacytoid dendritic cells. It is expressed intracellularly, within the endosomal compartments and functions to alert the immune system of viral and bacterial infections by binding to DNA rich in CpG motifs. This nucleotide-sensing TLR is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides (also called oligodinucleotides, ODNs), and consequently signals via MYD88 and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response and eventually activation of a Th1-biased adaptive immune attack. Specific TLR9 agonists have been shown to have substantial antitumor activity, making the TLR9 signaling pathway an interesting target for therapeutic research.

Pathways: TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades